NO20052515L - Frigjoringskontrollerte sammensetninger - Google Patents

Frigjoringskontrollerte sammensetninger

Info

Publication number
NO20052515L
NO20052515L NO20052515A NO20052515A NO20052515L NO 20052515 L NO20052515 L NO 20052515L NO 20052515 A NO20052515 A NO 20052515A NO 20052515 A NO20052515 A NO 20052515A NO 20052515 L NO20052515 L NO 20052515L
Authority
NO
Norway
Prior art keywords
release
matrix
agent
release controlled
core
Prior art date
Application number
NO20052515A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052515D0 (no
Inventor
Vincent Lenaerts
Patricia Laure Ouadji-Njiki
Jonathan Bacon
Rachid Quzerourou
Sonia Gervais
Miloud Rahmouni
Damon Smith
Original Assignee
Labopharm Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Europe Ltd filed Critical Labopharm Europe Ltd
Publication of NO20052515D0 publication Critical patent/NO20052515D0/no
Publication of NO20052515L publication Critical patent/NO20052515L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO20052515A 2002-10-25 2005-05-25 Frigjoringskontrollerte sammensetninger NO20052515L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28102602A 2002-10-25 2002-10-25
US50906202P 2002-10-25 2002-10-25
PCT/CA2003/001637 WO2004038428A2 (en) 2002-10-25 2003-10-27 Controlled-release compositions

Publications (2)

Publication Number Publication Date
NO20052515D0 NO20052515D0 (no) 2005-05-25
NO20052515L true NO20052515L (no) 2005-05-25

Family

ID=34976756

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052515A NO20052515L (no) 2002-10-25 2005-05-25 Frigjoringskontrollerte sammensetninger

Country Status (19)

Country Link
EP (1) EP1558935B1 (xx)
JP (1) JP2006507276A (xx)
KR (1) KR101120729B1 (xx)
AT (1) ATE400819T1 (xx)
AU (1) AU2003275854B9 (xx)
BR (1) BR0315657A (xx)
CA (1) CA2503361C (xx)
DE (1) DE60322091D1 (xx)
DK (1) DK1558935T3 (xx)
EC (1) ECSP055748A (xx)
ES (1) ES2310686T3 (xx)
HK (1) HK1086475A1 (xx)
MX (1) MXPA05004410A (xx)
NO (1) NO20052515L (xx)
NZ (1) NZ539869A (xx)
PT (1) PT1558935E (xx)
RU (1) RU2333745C2 (xx)
SI (1) SI1558935T1 (xx)
WO (1) WO2004038428A2 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
JP2005306778A (ja) * 2004-04-21 2005-11-04 Basf Ag 徐放性製剤及びその製造方法
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
BRPI0612802A2 (pt) 2005-07-07 2010-11-30 Farnam Co Inc composições farmacêuticas de liberação sustentada para medicamentos extremamente hidrossolúveis
CA2616204C (en) 2005-09-09 2015-12-01 Labopharm Inc. Sustained drug release composition
CN100437113C (zh) * 2006-04-11 2008-11-26 汪运山 一种检测血液中非那西丁与醋氨酚浓度比值的试剂盒
NZ703464A (en) 2006-04-26 2016-05-27 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
AU2013202441B2 (en) * 2006-04-26 2016-02-25 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
CN100387988C (zh) * 2006-07-25 2008-05-14 山东省医药工业研究所 一种布洛伪麻那敏复方制剂的含量检测方法
EP2120878B1 (en) 2007-02-09 2014-07-30 Alphapharm PTY LTD A dosage form containing two active pharmaceutical ingredients in different physical forms
CA2678092C (en) * 2007-10-16 2013-07-30 Labopharm Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
ES2419204T3 (es) 2008-05-27 2013-08-19 The University Of Melbourne Métodos para tratar a mamíferos con disfunciones de la trompa de Eustaquio
EP2448406B1 (en) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
CA2775890C (en) 2009-09-30 2016-06-21 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
EP2563349A4 (en) * 2010-04-23 2014-03-19 Paladin Labs Inc NON-INTRAVENOUS-MODIFIED FORM COMPRISING A SOLID FORMULATION OF A BIOLOGICALLY ACTIVE LIQUID AGENT AND USES THEREOF
RU2451680C1 (ru) 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
MX366159B (es) 2012-11-30 2019-07-01 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
CN114177155B (zh) * 2020-09-08 2023-10-03 越洋医药开发(广州)有限公司 一种布洛芬控释片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
CA2270975C (en) * 1997-07-02 2003-04-01 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
IL151150A0 (en) * 2001-01-31 2003-04-10 Roehm Gmbh Multiparticulate drug form comprising at least two differently coated pellet forms

Also Published As

Publication number Publication date
KR101120729B1 (ko) 2012-04-23
KR20050088281A (ko) 2005-09-05
DK1558935T3 (da) 2008-11-17
DE60322091D1 (de) 2008-08-21
MXPA05004410A (es) 2005-11-23
ECSP055748A (es) 2005-08-11
WO2004038428A3 (en) 2005-06-09
AU2003275854B2 (en) 2008-09-11
RU2333745C2 (ru) 2008-09-20
AU2003275854B9 (en) 2009-08-27
CA2503361C (en) 2012-02-28
HK1086475A1 (en) 2006-09-22
NO20052515D0 (no) 2005-05-25
CA2503361A1 (en) 2004-05-06
JP2006507276A (ja) 2006-03-02
AU2003275854A1 (en) 2004-05-13
EP1558935B1 (en) 2008-07-09
NZ539869A (en) 2007-09-28
ES2310686T3 (es) 2009-01-16
SI1558935T1 (sl) 2008-12-31
RU2005115883A (ru) 2006-01-27
BR0315657A (pt) 2005-09-13
PT1558935E (pt) 2008-10-16
EP1558935A2 (en) 2005-08-03
WO2004038428A2 (en) 2004-05-06
ATE400819T1 (de) 2008-07-15

Similar Documents

Publication Publication Date Title
NO20052515D0 (no) Frigjoringskontrollerte sammensetninger
NL2000281A1 (nl) Vaste farmaceutische samenstellingen die pregabaline bevatten.
MX9707585A (es) Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
AR001405A1 (es) Formulación oral de 2-metil-tieno-beno-diacepina.
NZ515359A (en) Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
RS54929B1 (sr) Formulacija i metod obložene tablete
TWI235068B (en) Sustained-release pharmaceutical composition
GEP20074022B (en) Pharmaceutical formulations comprising oxycodone and naloxone
MEP3608A (en) Modified-release tablet of bupropion hydrochloride
AR024492A1 (es) Formas de dosificacion farmaceutica para liberacion controlada que comprenden al menos un impulso ciclico
ATE536862T1 (de) Retardtabletten mit hydromorphon
ATE359075T1 (de) Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
WO2007025182A3 (en) Drug compositions containing controlled release hypromellose matrices
AR099437A2 (es) Matriz para la liberación sostenida, invariable e independiente de compuestos activos
ATE185266T1 (de) Schnell auflösende orale darreichungsform
MY142195A (en) Controlled-release compositions
UA86929C2 (ru) Композиция с контролируемым высвобождением
ATE479428T1 (de) Olanzapin enthaltende pharmazeutische zusammensetzung
BRPI0315657B8 (pt) formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição
ECSP961693A (es) Formulacion oral de 2- metil-tieno-benzodiaceptina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application